Scaffolds in Tissue Engineering

Stem-cell-related strategies may predominate these days in tissue engineering, but cell therapy companies know that providing the right microenvironment for nurturing tissue growth remains a difficult and essential challenge. Thus, start-ups remain committed to the developent of cellular matrices that provide the appropriate structure, environment, and bioactivity to encourage tissue growth. The four start-ups profiled in this issue represent a cross-section of strategies.

Outside of stem cells, it’s fair to say that the related areas of cell therapy and tissue engineering have not been particularly trendy areas for early-stage start-up investment in recent years—especially when it comes to the engineering of novel scaffolds that encourage the growth of tissue and organs. Of the companies highlighted in START-UP’s analysis of 2007’s trends in Series A financings, only the aesthetics company Follica Inc., which raised $5.5 million in December 2007, [See Deal] made the cut, and its strategy, rather than applying a bioactive cellular matrix of some sort, is to use a known drug to reprogram stem cells in the scalp to treat male- or female-pattern baldness. (See "The A-List: 2007’s Trend Shaping Series A Financings," START-UP, January 2008 Also see "The A-List: 2007's Trend Shaping Series A Financings" - Scrip, 1 January, 2008..) Nor did any tissue engineering start-ups make the prior year’s trends list, but one of 2005’s top movers, Tengion Inc., a developer of autologous organs, was recognized there for its $50 million Series B financing in June 2006. It was also the beneficiary of a $33 million Series C round in October 2007. [See Deal][See Deal] (See "Tengion Inc.," START-UP, September 2005 Also see "Tengion Inc." - Scrip, 1 September, 2005..)

Apart from Tengion, most of the tissue-engineering-related money flow in 2007 went to stem-cell-oriented companies. Fate Therapeutics Inc. launched...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

Where Next For Biologics In COPD After Roche’s Astegolimab Phase III Missfire?

 

The Phase III failure could dent Roche’s hopes of entering the COPD market with its novel therapy, despite its success in a large Phase IIb trial. It also marks another disappointment for the anti-IL33/ST2 approach.

Abivax Over The Moon As Obefazimod Storms Phase III

 
• By 

Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place

 

Regenxbio and Solid Biosciences believe they have a next-generation approach to AAV-based gene therapies – but must distance themselves from Sarepta’s safety and efficacy problems.

Replimune CRL Could Hold Warning For Accelerated Approvals

 

FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.

More from Scrip

Finance Watch: Sarepta’s Debt Woes Grow With Elevidys Shipment Pause

 
• By 

Public Company Edition: Sarepta restructured after stopping shipments of its Elevidys for some patients to ease future debt pressures, but now it has stopped shipments to all patients. Also, Madrigal secured up to $500m in new debt, Cogent closed a $230m offering and other financings.

Avalyn Raises $100m Series D To Advance Inhaled Pulmonary Fibrosis Candidates

 
• By 

Looking to improve on the efficacy and safety of Roche’s Esbriet and BI’s Ofev, Avalyn has inhalable formulations of those drugs in Phase IIb and Phase I, respectively.

AstraZeneca Pledges Big Investment In US Manufacturing Amid Tariff Threats

 

The drugmaker plans to build a large manufacturing center in Virginia as the centerpiece of an effort to invest $50bn in the US by 2030.